The UK government has put forth its intention to invest £260 million in cutting-edge medical research and development, as well as the manufacturing of innovative pharmaceuticals, gadgets, and diagnostics.
Through digital clinical trial services and Trusted Research Environments, the Department of Health and Social Care (DHSC) as well as the Department for Business, Energy and Industrial Strategy (BEIS) have allocated £200 million to allow research to provide improved access to NHS data. This will make essential data more secure, accessible for research, and protected from prying eyes.
The £200 million financial support for the health service could well deliver on government obligations established by the Life Sciences Vision to leverage NHS data to guide health research and innovation, building on pioneering work done during the pandemic to develop diagnostics and treatment for COVID-19, says UK Health and Social Care Secretary Sajid Javid. This, as per him, includes the RECOVERY trial that used NHS data via NHS DigiTrials and resulted in the development of Dexamethasone, the world’s only confirmed medication for COVID-19, within only 100 days, saving at least a million lives worldwide.
The investment will allow the NHS to more quickly provide new life-saving medications to patients, as well as encourage greater progressive and inclusive clinical research to address existing health inequities in patient care. Firms will be able to invest an extra £60 million in commercial-scale manufacturing, and they will also be able to get more money for biologics as well as medical devices.
The new Life Sciences Innovative Manufacturing Fund (LSIMF) would be in charge of allocating funds for manufacturing initiatives, allowing the UK’s life sciences sector to thrive while simultaneously creating jobs. This builds on the previous Medicines and Diagnostics Manufacturing Transformation Fund’s success.